Clinical Trial Update: Exploring the Treatment Duration of PD-1 Neoadjuvant Therapy in Stage II-III dMMR Rectal Cancer

View source ↗

Summary

This entry updates a clinical trial evaluating how long PD-1 neoadjuvant therapy should be given for stage II-III mismatch repair-deficient rectal cancer. The s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Rectal Cancer

Snippet

Sponsor: Xijing Hospital | Conditions: Immune-related Adverse Event, Neoadjuvant Therapy | Status: RECRUITING